Loading…
Loading…
VRPX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for VRPX and 80,000+ other tickers.
See exactly how VRPX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for VRPX and 80,000+ other tickers.
Virpax Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical enterprise, dedicated to pioneering diverse drug-delivery systems and novel drug-releasing technologies. Its core focus lies in developing advanced, non-opioid and non-addictive solutions for pain management, alongside therapies targeting central nervous system disorders. The company's current investigational pipeline features several preclinical product candidates. These include Epoladerm, a topical nonsteroidal anti-inflammatory drug (NSAID) designed to address chronic osteoarthritis of the knee, and Probudur, an…
Volatility and Risk Virpax Pharmaceuticals has a beta of 2.44, suggesting that its share price is 144% more volatile than the S&P 500. Comparatively, Zomedica has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Profitability This table compares Virpax Pharmaceuticals and Zomedica's net margins, return on
Risk and Volatility Virpax Pharmaceuticals has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500. Comparatively, Merck KGaA has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Insider and Institutional Ownership 32.2% of Virpax Pharmaceuticals shares are held
Volatility and Risk Virpax Pharmaceuticals has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Insider and Institutional Ownership 32.2% of Virpax Pharmaceuticals shares are held
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.0001 per share (“Common Stock”), that will become effective at 12:01 a.m. Eastern Time on.
BERWYN, Penn.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced positive results from a beagle dog dose range finding (“DRF”) study. Probudur is the company's long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediat.